A T-type calcium channel inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

TTA-A2

Item No. 42236

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-cyclopropyl-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]ethyl]-benzeneacetamide
CAS Number
953778-63-7
Molecular Formula
C20H21F3N2O2
Formula Weight
378.4
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥10 mg/mlEthanol: Soluble: ≥10 mg/ml
SMILES
O=C(CC1=CC=C(C2CC2)C=C1)N[C@H](C)C3=CC=C(OCC(F)(F)F)C=N3
InChi Code
InChI=1S/C20H21F3N2O2/c1-13(18-9-8-17(11-24-18)27-12-20(21,22)23)25-19(26)10-14-2-4-15(5-3-14)16-6-7-16/h2-5,8-9,11,13,16H,6-7,10,12H2,1H3,(H,25,26)/t13-/m1/s1
InChi Key
GEYDMBNDOVPFJL-CYBMUJFWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $69

    Add

    5 mg

    $307

    Add

    10 mg

    $546

    Add

    25 mg

    $1,023

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    TTA-A2 is an inhibitor of the T-type voltage-gated calcium (Cav) channels (IC50s = 89, 92, and 98 nM for Cav3.1, Cav3.2, and Cav3.3, respectively, in patch-clamp assays at -80 mV).1 It is selective for these channels over Cav1.2, Cav2.1, Cav2.2, and Cav2.3 in patch-clamp assays (IC50s = >30 µM for all at -90 mV). TTA-A2 (100 and 200 nM) reduces the viability of spheroid A549 lung cancer cells.2 It decreases body weight gain and fat mass and increases lean muscle mass in mice fed a high-fat diet when administered at a dose of 10 mg/kg.3 TTA-A2 (3 mg/kg) inhibits amphetamine- or MK-801-induced locomotor activity in rats.4 It reduces mean pulmonary arterial pressure and right ventricle hypertrophy in a rat model of hypoxic pulmonary hypertension induced by chronic housing in a hypobaric chamber.5 TTA-A2 (10 mg/kg) decreases the mean time spent in active wake and rapid eye movement (REM) sleep and increases the mean time spent in delta sleep in wild-type but not Cacna1g-/- and Cacna1i-/- double knockout mice when administered one hour before the inactive phase.1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kraus, R.L., Li, Y., Gregan, Y., et al. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J. Pharmacol. Exp. Ther. 335(2), 409-417 (2010).

    2. Kumari, N., Bhargava, A., and Rath, S.N. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line. Life Sci. 260, 118291 (2020).

    3. Uebele, V.N., Gotter, A.L., Nuss, C.E., et al. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J. Clin. Invest. 119(6), 1659-1667 (2009).

    4. Uslaner, J.M., Smith, S.M., Huszar, S.L., et al. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology 62(3), 1413-1421 (2012).

    5. Chevalier, M., Gilbert, G., Roux, E., et al. T-type calcium channels are involved in hypoxic pulmonary hypertension. Cardiovasc. Res. 103(4), 597-606 (2014).